Imatinib use during pregnancy and breast feeding: a case report and review of the literature
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, cilt.280, sa.2, ss.169-175, 2009 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 280 Sayı: 2
- Basım Tarihi: 2009
- Doi Numarası: 10.1007/s00404-008-0861-7
- Dergi Adı: ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.169-175
- Anahtar Kelimeler: Imatinib, Chronic myeloid leukemia, CML, Cancer, Pregnancy, Breast milk, Umbilical cord blood, Infant peripheral blood, Targeted therapy, CHRONIC MYELOID-LEUKEMIA, PATIENT, ISSUES, CML, LEUKAPHERESIS, MANAGEMENT, MESYLATE, CANCER, SAFETY
- Bursa Uludağ Üniversitesi Adresli: Evet
Özet
The development of imatinib as a therapeutic agent targeting BCR-ABL has increased the treatment options for chronic myeloid leukemia (CML) by significantly impacting outcomes, and imatinib is recommended by treatment guidelines as the first-line therapy. However, treatment of maternal CML with imatinib during gestation is not recommended because of the potential risk to the fetus.